Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00527501 · ClinicalTrials.gov registry record · Phase 2

IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 2 study, sponsored by Alcon Research.

Completed
Registry status
Phase 2
Development phase
136
Enrollment target

NCT00527501: Completed Phase 2 study, sponsored by Alcon Research.

NCT00527501 is a Phase 2 study that has completed, run by Alcon Research. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00527501, a Phase 2 study, has completed, sponsored by Alcon Research.

COMPLETED
Registry status
Phase 2
Development phase
136 participants
Enrollment target

Study Summary

The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.

Interventions

  • DRUG Travoprost/brinzolamide

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2007-08
Est. Completion 2007-12
Phase Phase 2
Alcon Research

275 total trials

What the finished NCT00527501 record still lists

NCT00527501 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.

The record links to 0 conditions, and to 1 intervention - of which Travoprost/brinzolamide is the first listed.

NCT00527501 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00527501 about?

NCT00527501 is a clinical study titled "IOP Lowering Efficacy of Travoprost/Brinzolamide Fixed Combination Ophthalmic Suspension in Patients With Open-Angle Glaucoma or Ocular Hypertension". The purpose of this study is to compare the safety and IOP-lowering efficacy of a fixed combination of Travoprost/Brinzolamide Ophthalmuc Suspension dosed BID and QD, to TRAVATAN dosed QD and a Vehicle dosed BID in patients with open-angle glaucoma or ocular hypertension.

What is the current status of trial NCT00527501?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2007-08. Estimated completion is 2007-12.

What interventions are being tested in trial NCT00527501?

The interventions under investigation include: Travoprost/brinzolamide (DRUG).

Who is sponsoring clinical trial NCT00527501?

This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00527501's enrollment target sits among peer trials

136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00527501, the US trial registry maintained by the National Library of Medicine. NCT00527501 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.